COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Patients in the intervention group, in addition to standard medication (serum therapy, analgesics, antipyretic, and vitamine), take oral Molnupiravir at a dose of 8
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Laboratory confirmation of Coronavirus disease-19 (COVID-19) virus by reverse transcription- polymerase chain reaction (RT-PCR) Moderate-severity disease (respiration rate more than 30 per minute, oxygen saturation more than 94%, or pulmonary infiltration less than 50% in both lungs) Age over 18 years Body mass index less than 40 kilogram per square meters No immunosuppressive diseases, including primary and secondary immunodeficiency, consumption of immunosuppressive drugs, organ transplants, chemotherapy or radiotherapy Patient willingness to participate in the study Existence of oral tolerance Non-pregnant and non-lactating women Not receiving antiviral drugs and other effective drugs in the treatment of COVID-19 in this clinical course No history of severe drug allergy and anaphylactic shock
Exclusion criteria
Exclusion criteria: Not completing the 5-day treatment period, not completing all visits or laboratory tests Development of severe drug hypersensitivity and anaphylactic shock during the study Occurrence of oral intolerance in the clinical course
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization during the follow-up period. Timepoint: Seventh day from the beginning of treatment. Method of measurement: Patient medical record.;Body temperature. Timepoint: Days 1 (start of treatment), 3, 5 and 7. Method of measurement: Thermometer.;Respiratory rate. Timepoint: Days 1 (start of treatment), 3, 5 and 7. Method of measurement: Physical examination by physician.;Oxygen saturation. Timepoint: Days 1 (start of treatment), 3, 5 and 7. Method of measurement: Pulseoxymeter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum CRP level. Timepoint: Days 1 (start of treatment) and 7. Method of measurement: Laboratory report.;Lymphocyte count. Timepoint: Days 1 (start of treatment) and 7. Method of measurement: Laboratory report.;Platelet count. Timepoint: Days 1 (start of treatment) and 7. Method of measurement: Laboratory report.;Neutrophil: Lymphocyte ratio. Timepoint: Days 1 (start of treatment) and 7. Method of measurement: Laboratory report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirreza Keyvanfar
Shahid Beheshti University of Medical Sciences
Outcome results
None listed